Morinaga Soichiro, Nakamura Yoshiyasu, Atsumi Yohei, Murakawa Masaaki, Yamaoku Koichiro, Aoyama Toru, Kobayashi Satoshi, Ueno Makoto, Morimoto Manabu, Yokose Tomoyuki, Miyagi Yohei
Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan
Department of Molecular Pathology, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
Anticancer Res. 2016 Mar;36(3):1083-8.
The overexpression of microRNA-21 (miR-21) in pancreatic cancer has been implicated in drug resistance to gemcitabine. Thus far, miR-21 has gained wide attention as a potential biomarker to predict the clinical response in patients with pancreatic cancer receiving gemcitabine. The aim of this study was to evaluate the predictive value of miR-21 expression, determined by locked nucleic acid in situ hybridization (LNA-ISH), in patients with pancreatic cancer who underwent adjuvant gemcitabine after curative surgery.
Tumor miR-21 expression was analyzed via LNA-ISH and correlated with the clinical outcomes of the patients treated with adjuvant gemcitabine.
The overexpression of miR-21 in pancreatic cancer, determined by LNA-ISH, was significantly and independently associated with a shorter disease-free survival in patients who received adjuvant gemcitabine after curative resection.
The LNA-ISH analysis of miR-21 may serve as a significant predictor for gemcitabine resistance in patients with pancreatic cancer undergoing adjuvant gemcitabine after curative resection.
胰腺癌中微小RNA-21（miR-21）的过表达与吉西他滨耐药有关。到目前为止，miR-21作为预测接受吉西他滨治疗的胰腺癌患者临床反应的潜在生物标志物已受到广泛关注。本研究的目的是评估通过锁核酸原位杂交（LNA-ISH）测定的miR-21表达在根治性手术后接受辅助吉西他滨治疗的胰腺癌患者中的预测价值。
通过LNA-ISH分析肿瘤miR-21表达，并将其与接受辅助吉西他滨治疗患者的临床结局相关联。
通过LNA-ISH测定，胰腺癌中miR-21的过表达与根治性切除后接受辅助吉西他滨治疗患者的无病生存期缩短显著且独立相关。
对miR-21进行LNA-ISH分析可能是根治性切除后接受辅助吉西他滨治疗胰腺癌患者吉西他滨耐药的重要预测指标。
